(Q41812469)

12 October 2017

The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna (English)

1 reference

12 October 2017

1 reference

1 reference

Bokemeyer C

1

1 reference

12 October 2017

Schmoll HJ

2

1 reference

12 October 2017

Ludwig E

3

1 reference

12 October 2017

Harstrick A

4

1 reference

12 October 2017

Dunn T

5

1 reference

12 October 2017

Casper J

6

1 reference

12 October 2017

language of work or name

English

0 references

publication date

1 May 1994

1 reference

British Journal of Cancer

12 October 2017

1 reference

12 October 2017

69

1 reference

12 October 2017

5

1 reference

12 October 2017

863-867

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1994.167

12 October 2017

0 references

cites work

Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Carcinogenicity of antineoplastic agents in man

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

A phase 2 study of intermittent high dose isophosphamide therapy of advanced colorectal cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

6 June 2018

Mesna--a short review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

The role of ifosfamide in testicular cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

High-dose ifosfamide with mesna uroprotection: a phase I study

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Antitumor activity of 2-mercaptoethanesulfonate (mesna) in vitro. Its potential use in the treatment of superficial bladder cancer.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

The enigma of ifosfamide encephalopathy.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968886

Cyclophosphamide and urinary bladder toxicity

6 June 2018

1 reference

12 December 2020

Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma

1 reference

12 December 2020

Clinical overview of mesna

1 reference

12 December 2020

Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide

1 reference

12 December 2020

Results of MIME salvage regimen for recurrent or refractory lymphoma

1 reference

12 December 2020

Cell lines of human germinal cancer

1 reference

12 December 2020

Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988

1 reference

12 December 2020

Mesna: continuous or bolus infusion?

1 reference

12 December 2020

Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1994.167

1 reference

12 October 2017

1 reference

12 October 2017

PubMed publication ID

8180015

1 reference